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Receptor tyrosine kinase activity is known to occur in
the absence of extracellular stimuli. Importantly, this
‘‘background’’ level of receptor phosphorylation is
insufficient to effect a downstream response, sug-
gesting that strict controls are present and prohibit
full activation. Here a mechanism is described in
which control of FGFR2 activation is provided by
the adaptor protein Grb2. Dimeric Grb2 binds to the
C termini of two FGFR2 molecules. This heterote-
tramer is capable of a low-level receptor transphos-
phorylation, but C-terminal phosphorylation and
recruitment of signaling proteins are sterically
hindered. Upon stimulation, FGFR2 phosphorylates
tyrosine residues on Grb2, promoting dissociation
from the receptor and allowing full activation of
downstream signaling. These observations establish
a role for Grb2 as an active regulator of RTK
signaling.INTRODUCTION
Members of the fibroblast growth factor receptor (FGFR) family
of receptor tyrosine kinases (RTKs) are key regulators of many
cellular processes, including proliferation, cell-cycle control,
migration, and differentiation (Turner and Grose, 2010). Aber-
rances in enzymatic activity of these receptors causes a variety
of human cancers and developmental defects (Robertson et al.,
2000; Pollock et al., 2007; Beenken and Mohammadi, 2009;
Zhao et al., 2010; Wesche et al., 2011). FGFRs are composed
of an extracellular region that consists of two or three immuno-
globulin (Ig)-like domains, a transmembrane region, and an
intracellular region that includes a tyrosine kinase domain and
flanking regulatory polypeptide sequences. FGFR signaling is
initiated by the binding of extracellular growth factors that are
conjugated to cell surface heparin sulfate proteoglycans
(HSPGs). On engaging the growth factor, the receptor dimerizes,
resulting in upregulation of intrinsic kinase activity and subse-
quent autophosphorylation of specific tyrosine residues in the
C termini. This provides sites for recruitment of proteins and1514 Cell 149, 1514–1524, June 22, 2012 ª2012 Elsevier Inc.activation of downstream signaling pathways such as the
mitogen-activated protein (MAP) kinase pathway. The relation-
ship between phosphorylation and signal transduction is not,
however, quite that simple. Phosphorylation of FGFR2 prior to
extracellular stimulation in numerous cell lines, even under
conditions of serum starvation, has been widely observed (Man-
sukhani et al., 2000; Takeda et al., 2007; Kunii et al., 2008; Bryant
et al., 2009; Ahmed et al., 2010). Importantly this ‘‘background’’
level of phosphorylation experienced by the receptor is insuffi-
cient to activate a downstream response until growth factor
stimulation occurs. Therefore, rather than being in a nonphos-
phorylated ‘‘ground state,’’ the receptor is, in effect, being held
in a nonsignaling, phosphorylated state primed for upregulation
and full activity. To ensure that this primed state is incapable of
effecting aberrant signals, a strict negative control mechanism
is required to prohibit full activation until FGFR2 is exposed to
growth factor.
Numerous alternative gene splicing events dictate structural
variants and, hence, function of FGFR2. Splicing of sequences
encoding the C terminus provides a major group of FGFR2 iso-
forms. Variants that result in deletions of the C-terminal
sequence show enhanced transforming activity (Cha et al.,
2008). These variants are expressed in increased amounts in
gastric cancer cell lines (Itoh et al., 1994; Ishii et al., 1995) and
in a majority of human breast carcinoma cells (Cha et al.,
2009). Recently, point mutations in the C-terminal region of
FGFR2 have also been linked with melanoma (Gartside et al.,
2009). This suggests an important role for the C terminus of
FGFR2 in control of receptor activity.
It was recently reported that the C-SH3 domain of growth
factor receptor-bound protein 2 (Grb2) binds to a proline-rich
sequence at the very C terminus of FGFR2 prior to growth factor
stimulation. Deletion of the last 10 residues of the receptor abro-
gated Grb2 binding and concomitantly downregulated the phos-
phorylation of FGFR2 in the basal state (Ahmed et al., 2010).
Furthermore, basal phosphorylation is also compromised in cells
expressing the oncogenic S252W mutation in FGFR2, which is
unable to bind Grb2. Therefore, Grb2 is strongly implicated in
controlling FGFR2 kinase activity prior to growth factor
stimulation.
Grb2 is ubiquitously expressed and plays a role in several
signaling pathways from RTKs. As an adaptor protein, it is
generally thought to play a passive role in signal transduction,
possessing no enzymatic activity of its own. It largely consists
of an SH2 domain sequentially sandwiched between N- and
C-terminal SH3 domains. The SH2 domain binds phosphory-
lated tyrosine residues on RTKs and their auxiliary docking
proteins, whereas the SH3 domains recognize proline-rich
sites on numerous proteins, including the guanine nucleotide
exchange factor son-of-sevenless (Sos) upstream of the MAPK
pathway (Li et al., 1993; Rozakis-Adcock et al., 1993).
Here we describe a mechanism whereby Grb2 exerts control
of FGFR2 kinase activity prior to growth factor binding. Dimeric
Grb2 recruits two receptor molecules and promotes phosphory-
lation of FGFR2 in the absence of extracellular stimulus. Binding
of Grb2 to the C terminus of FGFR2 regulates the activation of
a downstream signaling response. We demonstrate that Grb2
is a novel target for FGFR2 and show that, on stimulation by
FGF, the kinase activity of the receptor is upregulated, promoting
the phosphorylation of Grb2 and its concomitant release from
the receptor. This leaves FGFR2 free to effect downstream
signaling.
RESULTS
Grb2 Binding Is Required for Basal State Receptor
Phosphorylation
Several recent reports show the background level of FGFR2
phosphorylation in serum-starved cells (e.g., Ahmed et al.,
2010). This basal, ‘‘nonstimulated’’ phosphorylation of FGFR2
(pFGFR) was confirmed in HEK293T cells (Figure 1A). As the
anti-pFGFR antibody targets two tyrosine residues (Y653 and
Y654) in the kinase activation loop, our data suggest that
these residues are phosphorylated, which is consistent with
the kinase domain being in an active conformation. FGFR2
signals through the MAPK pathway, but, importantly the
observed background receptor phosphorylation was insufficient
to provide an active response as indicated by the absence
of phosphorylated ERK1/2 (pERK) prior to the addition of
FGF9 (Figure 1A). To demonstrate that the basal phosphorylation
of FGFR2 was not derived from extracellular stimuli that might
be present even under serum starvation conditions (such as
residual growth factors/cytokines or from interactions with
proteoglycan components of the extracellular matrix), we
blotted for FGFR2 phosphorylation using a truncated receptor
in which the extracellular, ligand binding domain had been
deleted (except for the membrane localization sequence at the
very N terminus; FGFR2DED). This truncation allows membrane
localization of the receptor but abrogates interactions with extra-
cellular stimulants. FGFR2DED is phosphorylated under basal
conditions, showing that basal FGFR2 phosphorylation is not
the result of residual extracellular signaling and is solely depen-
dent on intracellular conditions (Figure 1B). To demonstrate
that the phosphorylation of FGFR2DED is dependent of the
expression levels of Grb2, we used cells that were transfected
with FGFR2DED and increasing amounts of Grb2 DNA. The
concentration of pFGFR2DED increases with the expression of
Grb2 (Figure S1A available online). Although the truncated
FGFR2DED was basally phosphorylated, as seen with wild-
type (WT) receptor, it was incapable of upregulating ERK
(Figure S1B).We have previously reported that the C-terminal SH3 domain
of Grb2 (C-SH3) is able to bind to an amino acid sequence at
the very C terminus of FGFR2 (Ahmed et al., 2010). In cells ex-
pressing receptors in which the C-terminal Grb2-binding site is
deleted (Ahmed et al., 2010), or in which Grb2 has been knocked
down using shRNA, background phosphorylation is lost or
severely reduced (Figure 1C). Subsequent extracellular stimula-
tion of FGFR2 led to increased receptor phosphorylation. Thus,
the presence of Grb2 is able to enhance receptor phosphoryla-
tion in the basal state. To demonstrate this in vitro, we expressed
and purified recombinant dephosphorylated cytoplasmic region
of FGFR2 (FGFR2cyto residues 400–821) from Escherichia coli
(see Extended Experimental Procedures). FGFR2cyto was then
incubated for different time periods with ATP and Mg2+ in the
presence or absence of Grb2 and immunoblotted against phos-
photyrosine (pY) (Figure 1D). At the different time points, when
Grb2 is present, the level of receptor phosphorylation is mark-
edly enhanced compared to when it is absent (Figure 1D, inset).
Additional evidence for Grb2 binding being sufficient to
enhance FGFR2 phosphorylation is provided by demonstrating
that in vitro phosphorylation of the receptor is abrogated in the
absence of a functional Grb2-binding site. To demonstrate that
the binding of Grb2 was necessary for FGFR2 phosphorylation,
we incubated the FGFR2 isolated kinase domain (which cannot
recruit Grb2) or FGFR2cyto with Grb2 and ATP/Mg
2+ and deter-
mined the extent of receptor phosphorylation in the presence
of increasing concentrations of Grb2. The level of phosphoryla-
tion of the kinase domain is unaffected by the increasing concen-
tration of Grb2 (Figure S1C), whereas increasing amounts of
Grb2 enhance the pFGFR2cyto concentration (Figures S1D and
S1E). This confirms that Grb2 binding is required for receptor
phosphorylation.
The Grb2-FGFR2 Complex Involves an Extended
Interface
Although structural models for the apo-Grb2 C-SH3 have been
reported (Kohda et al., 1994; Maignan et al., 1995), no solution
nuclear magnetic resonance (NMR) spectral assignments have
been deposited/published. To provide a structural description
for the recognition of FGFR2 by Grb2, we used triple resonance
experiments to assign the backbone amides and both Ca and Cb
resonances (deposited in the Biological Magnetic Resonance
Bank [BMRB]) and mapped these on to the solution structure
of Grb2 C-SH3 (Protein Data Bank [PDB] ID: 1GFC). Complex
formation was confirmed by chemical shift changes in the
NMR resonances in the 1H-15N HSQC spectra of 15N-labeled
Grb2 C-SH3 upon addition of aliquots of the C-terminal 15
amino acids of FGFR2 (FGFR215 residues 807–821; Ac-
PSLPQYPHINGSVKT-NH2). The resonance shifts were gradual
with negligible broadening effects, characteristic of a fast
exchange regime on the NMR chemical shift time scale (typical
of weak binding with KDs of the order of >10 mM). Changes in
the weighted average chemical shifts over a threshold value of
0.01 ppm were observed for amide residues Y160, V161, F167,
E171, R178, N192, W193, A197, M204, F205, R207, Y209, and
the indole ring side chain NH of W193 (Figure S2A). The intermo-
lecular nuclear Overhauser effects (NOEs) for the complex were
difficult to determine due to the weak interaction; thus, weCell 149, 1514–1524, June 22, 2012 ª2012 Elsevier Inc. 1515
Figure 1. Basal Phosphorylation of FGFR2 Requires Grb2
(A) HEK293T cells stably expressing WT FGFR2 (GFP-tagged) were serum-starved overnight. Recombinant FGF9 (20 ng/ml) was used to stimulate cells for
15 min. Fifty micrograms of total cell lysate were used for immunoblotting studies. First panel: immunoblot probed with an anti-pFGFR2 antibody. Third panel:
immunoblot probed with an anti-pERK antibody to show the activation levels of FGFR2 and ERK in the total cell lysates. Anti-FGFR2 antibody (second panel),
anti-ERK1/2 antibody (fourth panel), and anti-tubulin antibody (fifth panel) were used to assess protein loading.
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Figure 2. FGFR2 C-Terminal Binds to an
Extended Interface on the Grb2 C-SH3
Domain, and the Full-Length Grb2 Forms
a Stable Dimer
(A) Structural model of Grb2 C-SH3 domain bound
to a 15-residue peptide from the FGFR2 very C
terminus. The complex structure was modeled
using the program HADDOCK. Left panel: surface
representation of Grb2 C-SH3 domain (red) in
complex with FGFR2 peptide (stick representa-
tion: carbon atoms in cyan). Y209 on the surface of
C-SH3 is shown in green. Right panel: Identical
structure to that shown in left panel rotated by
180. C-SH3 domain (shown in ribbons) and
FGFR2 peptide (stick: cyanwith proline residues in
magenta). See also Figure S2.
(B) Plot of hydrodynamic radius as a function
of concentration for dimeric Grb2 (red circles),
monomeric FGFR2cyto (black squares) and the
heterotetrameric complex formed by the mixture
of FGFR2cyto:Grb2 (blue triangles) in a 1:1 molar
ratio (for radius values, see Figures S3A and S3B
and Tables S2 and S3). Error bars shown on the
mean value of three independent experiments.
(C) Grb2 dissociation measured by MST. Unla-
beled Grb2 protein (55 nM to 100 mM) was titrated
into a fixed concentration of labeled Grb2
(100 nM). The top panel shows the raw data for
thermophoresis recorded at 20C using the red
LED at 10% and IR-Laser at 40%. The bottom
panel shows the isotherm derived from the raw
data and fitted according to the law of mass action
to yield an apparent KD,dimer (0.66 ± 0.20 mM).employed the high ambiguity driven docking (HADDOCK)
program (see Extended Experimental Procedures) to model the
structure of the complex. The backbone root-mean-square devi-
ation (RMSD) of the apo- and peptide-docked Grb2 C-SH3
domains was 0.88 A˚, suggesting that FGFR215 does not intro-
duce large changes in backbone conformation of the SH3
domain. Based on the model, the N-terminal proline-rich
segment of FGFR215 has an extended structure that adopts
a left-handed PPII helical conformation of class II proline-rich
ligands and fits into the canonical PXXPXR-binding site on C-
SH3. Interestingly, these interactions appear to orientate
FGFR2 Y812 of the peptide toward Y209 of Grb2 (Figure 2A).
This juxtaposition of phosphorylatable residues has an important(B) An empty vector, the extracellular domain-deletion FGFR2 construct (FGFR2D
hours posttransfection, cells were serum-starved overnight. Recombinant FGF9
used for immunoblotting studies. Top panel: immunoblot probed with an anti-pFG
FGFR2 antibody (middle panel) and anti-tubulin (lower panel) antibody were use
(C) Grb2-depleted cells were generated using shRNA in HEK293T cells stably expr
scrambled shRNA (FGFR2-Ci) were serum-starved overnight. Immunoblotting w
(20 ng/ml, 15min) stimulation. The anti-pFGFR2was used to detect the phosphory
to detect total FGFR2. A dramatic decrease in the basal level of FGFR2 phosphory
the phosphorylation levels of FGFR2 in both Grb2 knockdown and control cells;
knockdown cells is lower than that of in the control cells. The anti-tubulin antibo
(D) Purified FGFR2 (10 ng) cytoplasmic domain wasmixed with 5mMATP/10mM
incubated at 25C for the designated time period. The kinase activity shown b
antibody (top panel). Under these conditions, the receptors are capable of autop
increases. However, this effect is dramatically accentuated in the presence of
(middle panel) and anti-Grb2 antibodies (bottom panel) were used to assess totarole in dissociation of the complex on receptor stimulation (see
below). Our model shows that the C-terminal region of
FGFR215 (I815-T821) forms a left-handed b-like loop structure
that wraps around the RT loop of the domain with K820 and
T821 curled on to the other side of the SH3 domain. This confor-
mation is stabilized through electrostatic interactions between
K820 and H814 with E171. This results in a large region around
the RT loop appearing to form an unusual, additional binding
pocket that has not been previously observed in Grb2 (Yuzawa
et al., 2001) or other SH3 domain-proline-rich peptide
complexes (Figures 2A and S2B–S2D). A comparison of this
structure with other reported SH3 domain complexes is given
in the Extended Experimental Procedures. This unusual bindingED) and WT FGFR2 construct were transfected into HEK293T cells. Forty-eight
(20 ng/ml) was used to stimulate cells for 15 min. Total cell lysates (50 mg) were
FR antibody show the activation levels of the different FGFR2 constructs. Anti-
d to assess total protein loading. See also Figure S1.
essingWT FGFR2. Grb2 knockdown cells (FGFR2-Grb2i) and control cells with
as performed on cells in the basal state after serum starvation and after FGF9
lation of FGFR2, and an anti-FGFR2 antibody (anti-FGFR2, top panel) was used
lation is observed in the Grb2 knockdown cells. Stimulation by FGF9 increases
however, similar to the basal state, the phosphorylation level of FGFR2 in the
dy (bottom panel) confirms equal protein loading.
Mg2+ with or without 2 mg of Grb2 in 100 ml final volume. Reaction mixtures were
y receptor phosphorylation was detected by immunoblotting with an anti-pY
hosphorylation, and, with increasing time, the level of phosphorylated FGFR2
Grb2 (see densitometric quantification in inset on the right side). Anti-FGFR2
l protein loading.
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mode was also predicted by high-resolution peptide docking
using the Rosetta-based FlexPepDock server (Figures S2B
and S2C).
Grb2 Induces FGFR2 Dimerization prior to Extracellular
Stimulation
The full-length Grb2 is capable of forming a discrete dimer
(Maignan et al., 1995; McDonald et al., 2008). The physiological
relevance of this structure has been unclear; however, it has
important mechanistic consequences in determining the control
of receptor phosphorylation. Dynamic light scattering (DLS)
performed over the concentration range 0.4–40 mM revealed
that a discrete Grb2 dimer (dynamic radius 3.1 nm) was the
dominant species (Figure 2B). Below this concentration, the
population of dimer diminished, resulting in monomeric protein.
We were able to fit microscale thermophoresis (MST) at concen-
trations up to 100 mM to give an apparent equilibrium dimer
dissociation constant, KD,dimer0.7 mM (Figure 2C).
Because Grb2 is able to form a stable dimer, it was important
to establish whether it was capable of forming a complex with
FGFR2 in this self-associated state. We previously reported
binding data for the interaction of Grb2 with peptides corre-
sponding to the very C terminus of FGFR2 (Ahmed et al.,
2010). A more physiologically relevant assessment of the inter-
action was provided using isothermal titration calorimetry (ITC)
to measure the binding of Grb2 to intact FGFR2cyto (Figure 3A;
Table S1). As FGFR2 (150 mM) was titrated into Grb2 (15 mM),
an initial complex was formed with a stoichiometry of 2:1
Grb2:FGFR2 and apparent equilibrium dissociation constant,
KD, of 0.1 mM (schematic in Figure 3A). This interaction is approx-
imately 40-fold tighter than the binding of Grb2 to the FGFR215
peptide (Ahmed et al., 2010), suggesting that additional interac-
tions might be possible in the context of FGFR2cyto. As more
receptor was titrated, the 2:1 complex became saturated by
FGFR2, giving a final complex with a stoichiometry of unity.
This second binding event has a weaker affinity (25 mM). The
physiological relevance of this apparent anticooperativity is
unknown but could result from conformational change of the in-
teracting molecules or steric hindrance on assembly of the
complex in this in vitro experiment. Because Grb2 exists as
a dimer under the concentration conditions used in the ITC
experiment (see above) and binding to FGFR2 is only detected
for the Grb2 C-SH3 domain, the ITC data can be explained
by assuming that, as more FGFR2 is titrated into the 2:1
Grb2:FGFR2 complex, the unbound Grb2 C-SH3 domain binds
an additional receptor molecule forming a 2:2 heterotetrameric
complex (schematic in Figure 3A). DLS was used to confirm
the in vitro assembly of the heterotetramer (Figures 2B and
S3A–S3C). This complex is consistent with the Grb2 dimer
binding to FGFR2 in a conformation in which the C-SH3 domains
are exposed and accessible to the receptor as seen in the crystal
structure of intact Grb2 (Maignan et al., 1995).
We have shown that Grb2 is essential for the observed phos-
phorylation of FGFR2 prior to stimulation. Grb2 also exists as an
isolated dimer in solution, which forms a 2:2 heterotetrameric
complex binds with FGFR2 under saturating concentrations of
receptor. Thus, a model whereby Grb2 is able to recruit two
receptor molecules to predimerize and effect restricted kinase1518 Cell 149, 1514–1524, June 22, 2012 ª2012 Elsevier Inc.activity in the absence of extracellular stimulus is appealing. To
test this model, we used an in vitro fluorescence spectroscopic
method based on the mixing of FGFR2cyto fused to either green
or blue fluorescent protein (GFP or BFP, respectively). Excitation
of BFP results in an emission spectrum that overlaps with the
excitation wavelength of GFP. Thus, bringing the two fusion
proteins into close proximity can produce fluorescence reso-
nance energy transfer (FRET), resulting in GFP emission at
510 nm. The two FGFR2 samples (5 and 10 nM) were mixed
and irradiated at 383 nm to excite the BFP donor. In the solution
of BFP-FGFRcyto and GFP-FGFR2cyto in the absence of Grb2,
the fluorescence spectrum looks similar to that for BFP-
FGFR2cyto alone, suggesting that the receptors are not colocal-
izing and thus no FRET signal is apparent (Figure 3C). On the
addition of increasing concentrations of Grb2 (1 nM to 2 mM),
the GFP emission signal at 510 nm increased up to approxi-
mately 0.5 mM (Figure 3C, inset top; raw data are reported in
Figure S3D [note Grb2 KD,dimer0.7 mM; see above]). Consistent
with the aforementioned model of Grb2 dimer being capable of
bringing FGFR2 receptor molecules together, these data show
that, as the Grb2 concentration increases, an increase in FRET
efficiency occurs as a result of an increase in the population of
complexes involving GFP-FGFR2:BFP-FGFR2. This effect is
mirrored in the FRET distance (R; Figure 3C, inset bottom).
Additionally, we demonstrated recruitment of Grb2 to FGFR2
in cells. We transiently transfected HEK293T cells (in the pres-
ence and absence of FGFR2 expression) with both GFP- and
RFP-tagged Grb2. Using fluorescence lifetime imaging micros-
copy (FLIM), FRET associated with Grb2 self-association
(expected to be dimer) was observed to be cytoplasmically
dispersed throughout cells without FGFR2, but membrane local-
ized in the presence of FGFR2 (Figures S4A and S4B).
Based on our model in which Grb2 dimers recruit receptors,
adding an excess of Grb2 dimer to a preexisting heterotetramer
will result in saturation of FGFR2 molecules by Grb2 dimers
forming Grb2:FGFR 2:1 complexes (schematic in Figure 4A).
These complexes are inhibitory to Grb2-induced receptor dimer-
ization and will result in a reduction in the FRET signal. Figure 4A
shows that with the Grb2 concentration regime from 1–40 mM,
the fluorescence acceptor signal increases up to 10 mM but
decreases dramatically asmoreGrb2 is added and the receptors
are no longer capable of forming heterotetramers.
The in vitro experiments suggest that expression of high
concentrations of Grb2 in cells will be inhibitory to background
receptor phosphorylation. To demonstrate this in a cellular
context, we used increasing concentrations of Grb2-containing
plasmid (1 ng–5 mg) to induce different levels of Grb2 expression
in serum-starved stable HEK293T cells expressing FGFR2 (Fig-
ure 4B, lower panel). At low concentrations of Grb2, the level
of activation loop tyrosine phosphorylated FGFR2 (pFGFR2)
was low. As the amount of Grb2 in the cell was increased,
FGFR2 phosphorylation increased (e.g., see 0–100 ng in Fig-
ure 4B, top panel, and 4C), consistent with more prestimulated
receptor dimer formation. It is important to note that, in these un-
stimulated cells at increased Grb2 concentrations, although the
basal background phosphorylation of FGFR2 increases, there is
no apparent downstream signaling effected (as seen by lack of
pERK; Figure 4B, middle panel). This only occurs once growth
Figure 3. Full-Length Grb2 Forms a 2:2
Complex with FGFR2cyto
(A) ITC measurement of the interaction between
the dephosphorylated FGFR2 cytoplasmic do-
main and Grb2. Purified FGFR2cyto domain was
dephosphorylated using CIP. Twenty-eight 10 ml
injections of FGFR2cyto domain (150 mM) were
titrated into full-length Grb2 (15 mM) at 15C. Top
panel: baseline-corrected power versus time
plot for the titration (black) and the heat of dilution
of FGFR2cyto titrated into buffer (red; offset
by 0.05 mcal/s). Bottom panel: the integrated
heats and the molar ratio of the FGFR2cyto domain
to Grb2. The data were corrected for the heats of
dilution of the dephosphorylated FGFR2cyto and
fit to a two-site binding model. The schematic
shows the titration of Grb2 dimer (SH3 domains,
red; SH2 domain, yellow) with FGFR2cyto (blue).
The initial complex when Grb2 is in excess is 2:1
Grb2:FGFR2cyto. As more FGFR2cyto is added,
a 2:2 complex is formed. See also Table S1.
(B) Grb2 was tyrosine-phosphorylated by the
FGFR2cyto domain in the presence of ATP and
MgCl2 for 1 hr. Phosphorylated FGFR2cyto was
prepared by incubating ATP and MgCl2 on ice for
1 hr, followed by buffer exchange. FGFR2cyto
domain was injected from the ITC syringe into
full length pGrb2 at 15C. Top panel: baseline-
corrected power versus time plot for the titration
(black) and the heat of dilution of FGFR2cyto into
buffer (red—offset by0.04 mcal/s). Bottompanel:
the integrated heats and the molar ratio of the
FGFR2cyto domain to Grb2 for the pFGFR2/pGrb2
interaction (black) and the heat of dilution of
pFGFR2 (red). No binding was apparent.
(C) FRET analysis of Grb2-induced dimerization
of BFP-FGFR2cyto and GFP-FGFR2cyto. BFP-
FGFR2cyto (10 nM) and GFP-FGFR2cyto (5 nM)
were initially mixed in a 2:1 molar ratio at 15C.
FRET donor (BFP-FGFR2cyto) was excited at
383 nm, and it emitted at 440 nm (black line). In
the absence of Grb2, no emission of the FRET
acceptor (GFP-FGFR2cyto) signal was recorded at
510 nm (yellow). The addition of increasing
concentrations of Grb2 (1 nM Grb2, magenta;
10 nM, cyan; 100 nM, green; 500 nM, dark blue)
results in increasing FRET signals at 510 nm as
FGFR2cyto is dimerized in the presence of Grb2.
This suggests a role for Grb2 in recruitment of
BFP- and GFP-GFR2cyto. Inset top: The titration curves of the control experiments containing the different Grb2 concentrations were subtracted from the raw
data. Grb2 concentrations are color coded as described earlier. The graph shows gradual decreasing of the FRET donor emission at 440 nm and the gradual
increasing of FRET donor emission at 510 nm as the concentration of Grb2 is increased from 1 nMGrb2 to 500 nMGrb2. Inset bottom: calculated FRET efficiency
and FRET distance (R) for the Grb2-induced FGFR2cyto association over a Grb2 concentration range of 0–200 mM.
See also Figure S3D.factor is added. As even higher concentrations of Grb2 were
expressed, the level of receptor phosphorylation was reduced
(Figures 4B, top panel, and 4C). This is consistent with the
aforementioned FRET data and the proposed model for Grb2
at high concentrations inhibiting the formation of Grb2:FGFR2
heterotetramers (schematic in Figure 4B). Because the inhibited
complexes containing only one receptor are incapable of inter-
molecular kinase activity, background phosphorylation is abro-
gated (Figures 4B and 4C). Additional experiments show that
this inhibitory effect of high Grb2 concentrations on receptorphosphorylation is not due to extracellular ligand binding (Fig-
ure S1A), the FGFR2 fusion tag (Figure S5A), or overexpression
of FGFR2 (Figures S5B and S5C).
Phosphorylation of Grb2 by FGFR2 Abrogates Complex
Formation
From the proposed NMR structural model, a potential mecha-
nism for the release of Grb2 from FGFR2 is apparent. This model
shows that juxtaposed within the binding interface are two tyro-
sine residues (Grb2 Y209 and FGFR2 Y812; Figure 2A). As theCell 149, 1514–1524, June 22, 2012 ª2012 Elsevier Inc. 1519
Figure 4. High Concentrations of Grb2
Inhibit Receptor Dimerization
(A) Increasing concentrations of Grb2 (1 to 40 mM)
were mixed with BFP-FGFRcyto (10 nM) and GFP-
FGFRcyto (5 nM). The mixtures were excited at
383 nm, and the emission of GFP-FGFRcyto was
detected at 510 nm. The plot shows the FRET
emission fluorescence plotted against Grb2
concentration. At low concentrations of Grb2
(below 10 mM), the increasing FRET signal shows
increasing populations of FGFRcyto molecules
being brought into proximity, forming the 2:2
Grb2:FGFRcyto complex. As the concentration of
Grb2 increases (above 20 mM), the FRET signal is
reduced. This is consistent with increasing the
population of 2:1 Grb2:FGFRcyto complex (see
inset schematic), which is inhibitory to receptor
dimerization and, hence, the FRET signal.
(B) HEK293T cells stably expressing GFP-FGFR2
were transiently transfected with 1 ng–5 mg of
plasmid containing WT Grb2 DNA as indicated.
Cells were serum-starved overnight. FGF9
(20 ng/ml) was used to stimulate the starved cells
for 15 min. Total cell lysates (50 mg) were used for
immunoblotting studies. Upper panel: immunoblot
probed with an anti-pFGFR2 antibody shows
increasing concentration of pFGFR2 as the
transfected Grb2 DNA increases to 100 ng. After
this Grb2 concentration, the level of pFGFR2
decreases. This decrease in cellular pFGFR2
results from the same mass action effects as seen
in Figure 4A whereby increasing concentrations
of Grb2 protein expressed form more 2:1
Grb2:FGFR2 complex, which inhibit dimerization
and, hence, phosphorylation of the receptor (see
schematic). See also Figures S4 and S5.
(C) Graphical representation of the data shown in
Figure 4B. Densitometric data for the pFGFR2, normalized against total FGFR shows the concentration of pFGFR2 reaches a maximum as the cellular Grb2
concentration is increased. The reduction in pFGFR2 results from the accumulation of 2:1 Grb2:FGFR2 complex in the presence of excess Grb2. This is inhibitory
to FGFR2 dimerization and, hence, phosphorylation.side chains of these residues come into close proximity, post-
translational modification of these residues with large negatively
charged phosphate groups would lead to a charge repulsion or
steric clash and, hence, disruption of binding. Therefore, if upre-
gulation of the receptor can phosphorylate Grb2 and/or FGFR2,
this would provide a switch for the release of the control of the
basal receptor activity. This mechanism requires that Grb2 is
a substrate for FGFR2 kinase activity. Grb2 has been shown to
be phosphorylated by other tyrosine kinases. For example,
Grb2 is a substrate for EGFR (Haines et al., 2009), and Bcr/Abl
phosphorylates Grb2 SH3 domain tyrosines Y7, Y52, and Y209
(Li et al., 2001). We incubated increasing concentrations of
both FGFRcyto and the isolated kinase domain of FGFR2
(FGFRkin) with Grb2 in the presence of ATP and Mg
2+ for
15min and blotted with an anti-pY antibody to assess phosphor-
ylation of Grb2. Figure 5A shows that FGFRcyto, but not FGFRkin,
was able to phosphorylateGrb2 in vitro. Thus, Grb2 is a substrate
for FGFR2 kinase activity; furthermore, the C-terminal FGFR2
Grb2-binding site is required for phosphorylation to occur.
Grb2 has seven tyrosine residues that are potential substrates
for FGFR2 kinase (Figure 5B). Truncated versions of Grb2 were1520 Cell 149, 1514–1524, June 22, 2012 ª2012 Elsevier Inc.made to confirm that tyrosine residues on the C-SH3 domain
were capable of being phosphorylated by FGFR2. The N-SH3,
SH2, and C-SH3 domains of Grb2 were exposed to FGFR2cyto,
ATP, and Mg2+ on ice for 15 min (see Figure 5B for positions
of phosphorylatable tyrosine residues on full-length Grb2). The
products of the reaction were analyzed by immunoblotting and
probed with an anti-pY antibody. A phosphorylated species
was clearly observed corresponding to the C-SH3 domain, sug-
gesting that one of the two tyrosine residues (160 or 209) on this
construct was phosphorylated. A further band was also seen at
a higher molecular weight which corresponds to a smaller pop-
ulation of a doubly phosphorylated species (i.e., both Y160 and
Y209). Thus, FGFR2 is capable of phosphorylating Y209 in the
Grb2 C-SH3 domain.
To determine whether FGFR2 was capable of Grb2 phosphor-
ylation in a cellular context, HEK293T cells expressing WT
FGFR2 or vector alone were stimulated with FGF9 for 5 min.
The immunoprecipitated Grb2 from FGF9-stimulated FGFR2
overexpressing cells shows at least two bands corresponding
to the phosphorylation of Grb2 observed in the in vitro experi-
ments (Figure 5C).
Figure 5. Grb2 Is Phosphorylated by FGFR2
(A) Both purified FGFR2cyto (residues 400–821) and FGFR2kin (residues 412–760) domains were tested for their effects on Grb2 phosphorylation. Different
amounts (0.01–4 nM) of FGFR2cyto and FGFR2kin weremixedwith 500 ng of Grb2 protein with or without ATP/MgCl2 in a 100 ml solution. Reactionswere incubated
on ice for 15min and samples were denatured and analyzed using immunoblotting. The data show that, although FGFR2cyto can phosphorylate Grb2 (see lanes 6
and 7), under the same conditions FGFR2kin cannot (lanes 13 and 14). This suggests that a direct interaction via the SH3 domain of Grb2 and the FGFR2
C-terminal tail is required for Grb2 phosphorylation. The results were analyzed by immunoblotting with an anti-pY antibody (top panel) and an anti-Grb2 antibody
as the Grb2 loading control (bottom panel).
(B) Top: Schematic representation of Grb2 and truncated forms thereof used to identify phosphorylated tyrosine residues. The tyrosine residues are numbered
and shown as green circles. Bottom (immunoblot): Phosphorylation of Grb2 by FGFR2 in vitro. Purified FGFR2cyto and the Grb2 N-SH3, SH2 and C-SH3 domains
were used to identify the phosphorylation status of Grb2. The FGFR2cyto (4 nM) was mixed with 200 ng of the individual domains of Grb2 with or without ATP and
Mg2+ in a 100 ml solution. Reactions were incubated on ice for 15 min, and samples were denatured and analyzed using immunoblotting. Both the N-SH3 and C-
SH3 domains can be phosphorylated by FGFR2 in 15 min in the presence of ATP/Mg2+ (middle panel, lanes 6 and 8), whereas the SH2 domain is not tyrosine
phosphorylated (middle panel, lane 7). The results were analyzed by immunoblotting with an anti-pY antibody (top and middle panels). The loading control was
carried out with Ponceau staining in the absence of a suitable antibody (bottom panel).
(C) Cellular phosphorylation of Grb2. HEK293T cells were cotransfected with FGFR2 and Grb2 (Strep-tagged) or vector and Grb2 (Strep-tagged), starved
overnight, and then stimulated by FGF9 for 5min. Cells were then lysed in the presence of protease and phosphatase inhibitors. Total cell lysate (50 mg) were used
for immunoblotting studies. Total cell lysate (1 mg) were used for immunoprecipitation studies. The data show clear phosphorylation of Grb2 as revealed by
anti-pY antibody. Left top panel (whole-cell lysate study): The expression of FGFR2 was confirmed using an anti-FGFR2 antibody. Lower panel: Grb2 from the
FGFR2-expressing cells appears as at least two bands (arrows 1 and 2), suggesting that the higher mobility species (arrow 1) may be tyrosine phosphorylated.
Right top panel (immunoprecipitation study): The immunoprecipitated Grb2 (anti-Strep antibody) from FGFR2-expressing cells also show at least two bands
(arrow 1 and 2), suggesting that Grb2 has been tyrosine phosphorylated in the FGFR2-expression cells. Lower panel: An anti-pY antibody was used to confirm
that the higher mobility species (arrow 1) is/are tyrosine-phosphorylated Grb2.
(D) HEK293T cells stably expressing FGFR2-GFPwere transiently transfected with 8 mg ofWT, all 7F, Y7F, Y17F, Y52F, Y118F, Y134F, Y160F, Y209F, and Y7/52/
160F mutated Grb2 DNA as indicated. Cells were serum-starved for overnight. FGF9 (20 ng/ml) was used to stimulate the starved cells for 15 min. Total cell
lysates (50 mg) were used for immunoblotting studies. The immunoblot was probed with an anti-pFGFR2 antibody (top panel) and, with an anti-pERK antibody
(central panel) to show the activation levels of FGFR2 and ERK. Anti-Grb2 blot (bottom panel) shows the overexpression of the various Grb2 constructs.
Anti-tubulin antibody was used to confirm equal loading (central panel).Finally, we used ITC to assess the binding between full-length
phosphorylated Grb2 (pGrb2) and pFGFR2cyto to demonstrate
that, in the phosphorylated state, the proteins were unable to
interact. Incubation of both proteins for 1 hr in the presence ofATP and Mg2+ ensured that they were phosphorylated. This
was confirmed by mass spectroscopic analysis. No binding
was discernable for pFGFR2 and pGrb2 by ITC under the
conditions previously used to measure binding between theCell 149, 1514–1524, June 22, 2012 ª2012 Elsevier Inc. 1521
Figure 6. Model for Molecular Mechanism of the Control of FGFR2
Activation by Grb2
(A) Basal state of the FGFR2-Grb2 complex. Dimeric Grb2 (SH3 domains—
red; SH2 domain—yellow) is bound via its C-SH3 domain to the C-terminal
region of the receptor (blue), resulting in a 2:2 heterotetramer. The receptor is
predimerized in this state. The kinase domains of the FGFR2 (blue ovals) have
sufficient mobility to permit phosphorylation of a subset of receptor tyrosine
residues (including Y653 and Y654).
(B) Extracellular FGF (orange) and HSPG (red line) bind to FGFR2. The resulting
conformational change results in Grb2 becoming phosphorylated by the
FGFR2 kinase domain.
(C) Phosphorylated Grb2 can no longer bind to the receptor. FGFR2 kinase
domains in the absence of the Grb2 are able to become fully active accessing
tyrosine residues formally buried in the Grb2-receptor interface by trans-
phosphorylation.unphosphorylated polypeptides (Figure 3B). This is therefore
consistent with a mechanism whereby phosphorylation of Grb2
releases it from the receptor.
According to the proposed mechanism, a Grb2 mutation
Y209F should preclude the release of Grb2 from the extracellu-
larly stimulated receptor, as phenylalanine cannot be phosphor-
ylated by FGFR2 and, hence, no repulsive interaction will occur.
To measure the effect of Y-F substitutions on Grb2, we mutated
all of the available tyrosine residues on Grb2, either indepen-
dently or in selected groups. These Grb2 mutants were trans-
fected into stable HEK293T cells overexpressing WT FGFR2.
Stimulation of the receptor by FGF9 shows a pronounced effect
on receptor phosphorylation in the presence of one of the
mutants (Figure 5D). In the two cell lines in which Y209F was
present (i.e., ‘‘all 7F’’ and ‘‘Y209F’’), a clear phenotype was re-
vealed in which poststimulatory phosphorylation of FGFR2 was
inhibited. However, the Y209F mutant still showed the basal
phosphorylation, indicating that the mutant did not abrogate
Grb2 binding to FGFR2. This difference between pre- and
poststimulation pFGFR2 concentrations is not apparent in the
context of the other Y-to-F mutations, and the bands are similar
to that seen for the WT Grb2. These results show that, if Grb2 is
unable to be removed from the receptor, then the ability of the
receptor to phosphorylate itself (either cis or trans) in the stimu-
lated state is strongly affected. This is likely to be in part due
to Grb2 sterically hindering FGFR2 C-terminal recruitment to
the kinase domain and thus inhibiting access to the tyrosine
residues.
DISCUSSION
Phosphorylation of tyrosine residues on an RTK provides sites
for recruitment of signaling proteins and, under appropriate
conditions, transduction of a downstream response. Receptor
activity in the absence of extracellular stimulation suggests
that control of the phosphorylation is fundamental to cellular
function and survival. RTKs exhibit idiosyncratic modes of basal
kinase inhibition, stimulant recognition, and upregulation of
kinase activity (Zhang et al., 2006; Lemmon and Schlessinger,
2010). Here we report a novel control mechanism in which
FGFR2 is held in a dimeric state by binding of a Grb2 dimer at
the very C terminus of the receptor (see schematic model in
Figures 6A–6C). In this heterotetrameric state, the receptor is
capable of a low level of kinase activity but prohibited from
effecting a downstream MAP kinase response. In addition, the
binding of Grb2 in the largely unstructured C-terminal region of
FGFR2 inhibits access to tyrosine residues that, on phosphory-
lation, form binding sites for recruitment of downstream
signaling proteins. When the receptor is stimulated by a growth
factor, the kinase activity is upregulated resulting in phosphory-
lation of Grb2 Y209. In its phosphorylated state, Grb2 is no
longer capable of binding FGFR2. The liberated receptor can
then undergo the required conformational changes to achieve
a signaling-competent phosphorylated state. The structural
basis of the complex of full-length Grb2 bound to the cyto-
plasmic region of FGFR2 has yet to be elucidated; however,
based on our knowledge, a model can be constructed
(Figure S6).1522 Cell 149, 1514–1524, June 22, 2012 ª2012 Elsevier Inc.This novel regulatory mechanism is dependent on the ability of
Grb2 to bind via its C-terminal SH3 domain to the C terminus of
FGFR2, its potential to dimerize under cellular conditions
(KD,dimer 0.7 mM), and its ability to be phosphorylated by acti-
vated FGFR2 and, hence, released from the receptor. Whether
this mechanism of RTK predimerization through Grb2 is unique
to FGFR2 remains unclear; however, several other receptors
have sequences that could form binding sites for Grb2 C-SH3
domain. For example, insulin receptor, insulinlike growth factor
receptor, and epidermal growth factor receptors all have
cognate SH3 domain-binding PXXP motifs in their C termini.
Furthermore, SH3 domains are quite promiscuous in their
binding, and recent screening studies have demonstrated that
Grb2 C-SH3 is able to bind sequences found on RTKs as diverse
as R/KXXR/K with micromolar affinity (Jia et al., 2005). Thus, it is
tempting to speculate that FGFR2 is not the only receptor for
which Grb2-mediated dimerization occurs.
The involvement of Grb2 in FGFR2 signal regulation provides
a further variation on the theme of RTK regulation (Lemmon
and Schlessinger, 2010); however, uniquely in this case, a third
party adds a novel regulatory layer to the system formed by
receptor and growth factor (excluding the involvement of cell
matrix proteoglycans). There are examples where receptors
and signaling molecules are recruited and assembled through
adaptor protein binding; however, these occur as a consequence
of ligand-induced receptor activation (Hu et al., 2003; Houtman
et al. (2006). The role of Grb2 appears to be twofold: dimerization
of FGFR2 and controlling the phosphorylation so that FGFR2 is
incapable of a MAPK downstream response. Predimerization
of the receptor facilitates growth factor/HSPG recognition and
binding, and, hence, lower concentrations of extracellular stimuli
are required. Prephosphorylation of kinase domain tyrosines
means that the receptor does not start at a zero-phosphorylated
ground state, which is likely to have consequences both energet-
ically and with respect to the integrity of the order in which
tyrosine residues are phosphorylated (Furdui et al., 2006).
Grb2-mediated basal control of FGFR2 signaling provides
a dramatic alternative to the canonical view of RTK signaling
and control thereof. The involvement of an intracellular protein
in facilitating RTK dimerization and exerting control over kinase
activity suggests that tyrosine kinase-mediated signal transduc-
tion cannot be represented by otherwise random coming
together of receptors diffusing through the plasma membrane
being locked into dimeric (or higher order) complexes in the pres-
ence of growth factors. In the case of FGFR2, this process is
subject to additional influence. Furthermore, the role outlined
for Grb2 elevates it from a passive protein simply linking others
in signal transduction to an active regulator of receptor activity
and potential suppressor of aberrant signals that can lead to
cancer.
EXPERIMENTAL PROCEDURES
Cells
Human embryonic kidney 293T (HEK293T) cells and HEK293T cells express-
ing WT FGFR2 were maintained and grown in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal calf serum, 0.05 mg/ml gentamycin
sulfate (Cambrex), and 13 Pen/Strep Fungizone Mixture (Cambrex) at 37C
in a 5% CO2 humidified incubator.
Molecular Cloning
Gene fragments encoding FGFR2 and Grb2 constructs were amplified using
PCR and were cloned into pGEX4T1 and pET33b vectors. Bacterial GFP/
BFP expression vectors were generated on the pET28b vector backbone.
The extracellular domain-deletion FGFR2 construct was cloned into the
pEGFP-N3 vector. Site-directed mutagenesis was also used to generate the
various Grb2 Y-to-F mutants.
Protein Expression and Purification
63 histidine- and glutathione S-transferase (GST)-tagged constructs of
FGFR2 and Grb2 were expressed and purified from E. coli as described in
the Extended Experimental Procedures and by Ahmed et al. (2010).
ITC
ITC experiments were carried out using a VP Microcal instrument (Northamp-
ton, MA), and data were analyzed using ORIGIN7 software (Extended Experi-
mental Procedures). To avoid heats associated with the dissociation of dimeric
Grb2, FGFR2-derived polypeptides were titrated into the Grb2. All measure-
ments were repeated at least three times. The experiments were performed
as described elsewhere (Ladbury and Chowdhry, 1996) at 15C.
MST
The microscale thermophoresis (MST) method has been described in detail
elsewhere (Jerabek-Willemsen et al., 2011). The KD,dimer for Grb2 dimers
was measured using the Monolith NT.115 from Nanotemper Technologies.
Proteins were fluorescently labeled according to the manufacturer’s protocol.
Labeling efficiency was determined to be 2:1 (protein to dye) by measuring the
absorbance at 280 nm and 650 nm. A solution of unlabeled Grb2 was serially
diluted from about 100 mM to 55 nM in the presence of 100 nM labeled Grb2.
The samples were loaded into silica capillaries (Polymicro Technologies) afterincubation at room temperature for 1 hr. Measurements were performed at
20C in 20 mM HEPES buffer, pH 8.0, with 200 mM NaCl, 1 mM bME, and
0.05% Tween 20, by using 10% LED power and 40% IR-laser power.
Measurements were also carried out on 35% LED power and 20% IR-Laser
power for comparison. Data analyses were performed using Nanotemper
Analysis software, v.1.2.101.
DLS
DLS experiments were performed at 20C in a Wyatt Technologies DynaPro
Titan instrument. Experiments were carried out in standard PBS buffer. Grb2
samples were centrifuged at 16,1003 g for 1 hr at 20C to degas and remove
any residual aggregates. DLS data were collected and analyzed using
DYNAMICS V6.7.6 software for the DynaPro Titan instrument (Wyatt
Technology Corporation).
Fluorescence Spectroscopy
Steady-state fluorescence was measured in triplicate at 15C in 20 mM Tris-
HCl, pH 8.0, with 50 mM NaCl and 1 mM bME using the QuantaMaster-
4-CW from Photon Technology International. Spectra were measured from
400 to 550 nm with excitation at 383 nm. Excitation and emission bandwidths
were set to be 0.5 nm. The emission of 10 nM BFP-FGFR2cyto (donor) was
measured followed by a second measurement performed in the presence of
5 nM GFP-FGFR2cyto (acceptor). In the absence of Grb2, a small FRET signal
was observed. Grb2 was added to BFP/GFP-FGFR2cyto (which was kept at
constant 2:1 molar ratio). FRET was monitored as the Grb2 concentration
was increased from 1 nM to 2 mM. The Fo¨rster radius (R0), FRET efficiency
(E), and distance (R) were calculated using the software PTI Felix32 Analysis,
version 1.2, assuming that k2 is 2/3 (fast rotation limit), the refractive index of
water (n) is 1.33, quantum yields of 0.26, and extinction coefficient, ε (l),
of 31,000 M1cm1 at the wavelength of 383 nm. R0 was calculated to be
27.4 ± 1.50 A˚. Errors for E and R were estimated to be about 5%.
NMR Spectroscopy
The NMR experiments were performed on Bruker Avance III 700 MHz spec-
trometer equipped with a cryoprobe. All experiments were performed at
25C as described in the Extended Experimental Procedures. All NMR data
were processed using NMRpipe (Delaglio et al., 1995) and Azara software
(Wayne Boucher, Department of Biochemistry, University of Cambridge,
Cambridge, UK). The two- and three-dimensional (2D and 3D, respectively)
NMR data visualization and analyses were performed with the CCPN Analysis
program suite (http://www.ccpn.ac.uk/). Details on sequential assignment of
backbone residues of the human Grb2 C-SH3 (residues 156–217) and of the
HADDOCK and FlexPepDock docking methods are given in the Extended
Experimental Procedures.
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